Blue, you really didn't expand on what or where you felt I was wrong. So it;s kind of difficult to defend my position. LOL
The only thing you really mentioned was you felt I was off by a factor of 10. so I am assuming you felt I was wrong on the money aspect.
All I can say is your connection of the past performance of the company as being a detractor would be not effect the price in my opinion. The drug will speak for itself to any potential partner. either someone will want it and see the potential and value accordingly. They really do not care if he is a spend thrift or not.
The fact they may feel Odidi does not wisely spend is immaterial, they will only care about the working relationship and the drug will it pass. In this, the one thing he has gong for him is his science.
So really, I think the question is how much is Regabatin really worth? I do not feel a 10 million up front would be out of the question. but laying out a string of milestone payments like Angelo has, maybe we only get 2 million up front because at the end they want 50% of profit? That I have no clue.
me personally seeing how MNK and PAR can fudge sales or profit numbers. I would rather have larger up front and milestone stone payments and be content with a share of 20%.
we shall see. in my opinion the biggest obstacle we have had in the past, in regards to Regabatin, is Odidi's inability to close deals. Regabatin should have been partnered 2 years ago before Lyrica goes generic and Pfizer got their own ER version on the market.
Market Data 
Markets 
AI
